BioSpace News Archive

Endologix, Inc. today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease.

Adrian Adams To Serve as Independent Chairperson of the Board After Merger

Thermi®, an Almirall, S.A. company, today announced that it has received a notice of completion to a U.S. Food and Drug Administration (FDA) inquiry on products used in “vaginal rejuvenation” procedures.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced initial clinical data in patients treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B.

Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals today announced the completion of a series-A financing round, whereby the company secured funding of EUR 37 million

BC Platforms, a world leader in secure genomic data management and analytics, announces an agreement with Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), to make summary data about BioVU®, one of the world’s most comprehensive clinico-genomic research databases, available through its global biobank platform, BCRQUEST.com.

NBE Therapeutics AG, a biopharmaceutical company developing next-generation immune-stimulatory antibody-drug conjugates (iADCs™) for improved cancer therapy, today announces the appointment of Dr. Anthony Tolcher to NBE’s Scientific Advisory Board (SAB)

Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders

- Company Expects to Report Top-line Data in Mid-2019 and is Building the Commercial Capabilities to Support the Planned Launch of DCC-2618 in the United States -

Recommendation based on results from the Phase 3 CheckMate -214 clinical trial